Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.630 CHF
−217.08 M CHF
148.38 M CHF
199.04 M
About Sangamo Therapeutics, Inc.
Sector
Industry
CEO
Alexander D. Macrae
Website
Headquarters
Richmond
Founded
1995
FIGI
BBG007FJP446
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of GBY is 1.005 CHF — it has increased by 29.51% in the past 24 hours. Watch SANGAMO THERAPEUTI stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange SANGAMO THERAPEUTI stocks are traded under the ticker GBY.
We've gathered analysts' opinions on SANGAMO THERAPEUTI future price: according to them, GBY price has a max estimate of 8.86 CHF and a min estimate of 1.77 CHF. Watch GBY chart and read a more detailed SANGAMO THERAPEUTI stock forecast: see what analysts think of SANGAMO THERAPEUTI and suggest that you do with its stocks.
GBY stock is 22.83% volatile and has beta coefficient of 0.19. Track SANGAMO THERAPEUTI stock price on the chart and check out the list of the most volatile stocks — is SANGAMO THERAPEUTI there?
Today SANGAMO THERAPEUTI has the market capitalization of 399.51 M, it has decreased by −5.66% over the last week.
Yes, you can track SANGAMO THERAPEUTI financials in yearly and quarterly reports right on TradingView.
SANGAMO THERAPEUTI is going to release the next earnings report on Feb 19, 2025. Keep track of upcoming events with our Earnings Calendar.
GBY earnings for the last quarter are 0.03 CHF per share, whereas the estimation was −0.01 CHF resulting in a 362.30% surprise. The estimated earnings for the next quarter are −0.08 CHF per share. See more details about SANGAMO THERAPEUTI earnings.
SANGAMO THERAPEUTI revenue for the last quarter amounts to 41.86 M CHF, despite the estimated figure of 17.73 M CHF. In the next quarter, revenue is expected to reach 9.19 M CHF.
GBY net income for the last quarter is 7.95 M CHF, while the quarter before that showed −32.48 M CHF of net income which accounts for 124.49% change. Track more SANGAMO THERAPEUTI financial stats to get the full picture.
No, GBY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 16, 2024, the company has 405.00 employees. See our rating of the largest employees — is SANGAMO THERAPEUTI on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SANGAMO THERAPEUTI EBITDA is −105.09 M CHF, and current EBITDA margin is −52.26%. See more stats in SANGAMO THERAPEUTI financial statements.
Like other stocks, GBY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SANGAMO THERAPEUTI stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SANGAMO THERAPEUTI technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SANGAMO THERAPEUTI stock shows the strong sell signal. See more of SANGAMO THERAPEUTI technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.